ABBV-706 Yields Durable Responses and Is Deemed Tolerable in R/R SCLC

The seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate (ADC) ABBV-706 produced durable clinical benefit with a manageable safety profile in patients with relapsed/refractory small cell lung cancer (SCLC), according to updated …